Get the Stockscreener App
28.05
13.10%
3.25
Pre-market:
28.10
0.05
+0.18%
Agios Pharmaceuticals Inc stock is traded at $28.05, with a volume of 2.80M.
It is up +13.10% in the last 24 hours and down -4.69% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
See More
Previous Close:
$24.80
Open:
$26.5
24h Volume:
2.80M
Relative Volume:
2.72
Market Cap:
$1.67B
Revenue:
$54.03M
Net Income/Loss:
$-412.78M
P/E Ratio:
-3.9402
EPS:
-7.1189
Net Cash Flow:
$-377.29M
1W Performance:
+4.98%
1M Performance:
-4.69%
6M Performance:
-33.15%
1Y Performance:
-3.61%
1-Day Range:
$25.65
$28.82
1-Week Range:
$24.29
$28.82
52-Week Range:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
28.05 | 1.47B | 54.03M | -412.78M | -377.29M | -7.1189 |
VRTX
Vertex Pharmaceuticals Inc
|
423.24 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
686.36 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.02 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.19 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
290.80 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Reiterated | H.C. Wainwright | Buy |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Agios Pharmaceuticals Inc (AGIO) Q1 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic Advances - GuruFocus
AGIO SEC FilingsAgios Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Agios Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday - Yahoo Finance
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday - The Motley Fool
Agios plans Q2 sNDA filing for mitapivat in sickle cell disease while citing >$10B 2030 market opportunity - MSN
Earnings Call Summary | Agios Pharmaceuticals(AGIO.US) Q1 2026 Earnings Conference - 富途牛牛
Vanguard Capital Management (NASDAQ: AGIO) reports 3.09M shares, 5.27% ownership - Stock Titan
Agios Pharmaceuticals : 2026 Proxy Statement (a7ac5c) - marketscreener.com
Agios Pharmaceuticals Q1 2026 Financial Results: Net Loss, Revenue, and Key Financial Statements - Minichart
Agios Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Agios Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Agios Pharmaceuticals reports $20.7M revenue, $(1.69) EPS on 10-Q - TradingView
Agios Pharmaceuticals (NASDAQ: AGIO) grows Q1 2026 sales while funding deep rare-disease pipeline - Stock Titan
Earnings call transcript: Agios Q1 2026 earnings soar past expectations By Investing.com - Investing.com Canada
Agios Pharmaceuticals (AGIO) Q1 2026: GAAP EPS -1.69 vs -1.79 Es - GuruFocus
Agios Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Agios Reports Strong Q1 Revenue Growth and Strategic Advances - GuruFocus
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (AGIO) Agios Pharmaceuticals Posts Q1 Net Loss $1.69 a Share, vs. FactSet Est of $1.80 Loss - marketscreener.com
Earnings Flash (AGIO) Agios Pharmaceuticals, Inc. Reports Q1 Revenue $20.7M, vs. FactSet Est of $13.3M - marketscreener.com
Agios Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Agios Pharmaceuticals: Q1 Earnings Snapshot - marketscreener.com
Agios (NASDAQ: AGIO) doubles mitapivat revenue and funds 2026 pipeline catalysts - Stock Titan
New thalassemia drug writes 242 U.S. scripts as Agios plans sickle cell filing - Stock Titan
Agios Pharmaceuticals Q1 2026 earnings preview - MSN
Q3 2025 Agios Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
MSN Money - MSN
Agios falls as Leerink cites deaths linked to lead asset Pyrukynd - MSN
BofA Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO) - Insider Monkey
10 Oversold Small Cap Stocks to Buy Now - Insider Monkey
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Agios (AGIO) Q2 2025 Earnings Call Transcript - AOL.com
[ARS] AGIOS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Agios Pharmaceuticals (NASDAQ: AGIO) outlines 2026 virtual meeting, director elections and plan amendment - Stock Titan
Do Upbeat EPS Revisions Before Earnings Quietly Reframe Agios Pharmaceuticals’ (AGIO) Risk‑Reward Profile? - Yahoo Finance
Do Agios Pharmaceuticals’ (AGIO) EPS Revisions Hint At A Turning Point In Its Investment Story? - simplywall.st
Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) - Yahoo Finance
FY2027 Earnings Forecast for AGIO Issued By HC Wainwright - MarketBeat
Here's why Agios Pharmaceuticals crashed 23% today - MSN
Earnings Preview: Agios Pharmaceuticals (AGIO) Q1 Earnings Expected to Decline - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Palvella Therapeutics (PVLA) - The Globe and Mail
Agios Pharmaceuticals (AGIO) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Bank of America Cuts Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $41.00 - MarketBeat
Agios: Novo's Sickle Cell Win Changes The PK Activator Game (Rating Downgrade) - Seeking Alpha
Agios Stock Sinks 23% as NVO's PKR Activator Meets Goal in SCD Study - Yahoo Finance
H.C. Wainwright cuts Agios Pharma price target to $50 on competition - Investing.com Canada
Why Novo Nordisk's Surprise Win Hammered Agios Pharmaceuticals Stock - Investor's Business Daily
Novo Nordisk Shows Sickle Cell Efficacy Advantage Over Agios’s Mitapivat - Citeline News & Insights
Novo’s Once-Daily Sickle Cell Pill Hits Milestone. A Smaller Rival Is Sinking 24%. - Barron's
Agios Pharmaceuticals stock tumbles 25% after Novo data - Investing.com
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):